organization · Reporting owner
Shire Human Genetic Therapies, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Translate Bio, Inc.
Report date June 30, 2020 · Filed June 30, 2020
Jointly reported with TAKEDA PHARMACEUTICAL CO LTD
Section 16 reporting ended · disclosed 2020-06-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-06-30 · Sale · Disposed 6,824,992 · Balance 0 F1: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F2: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited.
F2: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2020 Filed Jun 30, 2020 20:24 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleCommon Stock | 6,824,992 | $20.68 | $141,140,834.56 |
DisclosureSEC source: 0001395064-20-000122 · wf-form4_159356305111852.xml · nonDerivative · entry 1 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F2 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 09:52 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleCommon Stock | 40,086 | $19.75 | $791,698.50 |
DisclosureSEC source: 0001395064-20-000084 · wf-form4_159136513441728.xml · nonDerivative · entry 1 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,824,992 F1 · price: Weighted average of sales prices. Actual prices range from $19.11 to $20.00. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 06:08 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleCommon Stock | 5,006 | $20.02 | $100,220.12 |
DisclosureSEC source: 0001395064-20-000082 · wf-form4_159117891482479.xml · nonDerivative · entry 4 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,865,078 F6 · price: Weighted average of sales prices. Actual prices range from $20.00 to $20.05. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 06:08 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleCommon Stock | 100,389 | $19.75 | $1,982,682.75 |
DisclosureSEC source: 0001395064-20-000082 · wf-form4_159117891482479.xml · nonDerivative · entry 3 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,870,084 F5 · price: Weighted average of sales prices. Actual prices range from $19.05 to $19.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 06:08 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleCommon Stock | 1,400 | $20.53 | $28,742.00 |
DisclosureSEC source: 0001395064-20-000082 · wf-form4_159117891482479.xml · nonDerivative · entry 2 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,970,473 F4 · price: Weighted average of sales prices. Actual prices range from $20.40 to $20.56. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 06:08 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleCommon Stock | 107,072 | $19.85 | $2,125,379.20 |
DisclosureSEC source: 0001395064-20-000082 · wf-form4_159117891482479.xml · nonDerivative · entry 1 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,971,873 F1 · price: Weighted average of sales prices. Actual prices range from $19.40 to $20.25. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer. F2 · ownership.direct: This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. F3 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 21:46 UTC | Translate Bio, Inc. TBIO · Entity 135439 | OtherCommon Stock | 183,619 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-18-008190 · dp93048_4.xml · nonDerivative · entry 1 Shire Human Genetic Therapies, Inc. · CIK 0001745009 · 10% owner Shire plc · CIK 0000936402 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,078,945 F1 · kind: These shares were issued upon the closing of the Issuer's initial public offering in satisfaction of contractual obligations, based on the initial public offering price of $13.00 per share, without payment of any additional consideration by Shire Human Genetic Therapies, Inc. at the time of issuance. F2 · ownership.direct: These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Shire plc. Shire plc is an indirect beneficial owner of the reported securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.